Skip to main content

Table 4 The marginal annual cost - effectiveness and benefit-cost of sif in Ottawa using the first model

From: A cost-benefit/cost-effectiveness analysis of proposed supervised injection facilities in Ottawa, Canada

Variables Annual cost of operation Sharing rate # of HIV averted # of HCV averted Cost-effectiveness ratio HCV Cost-effectiveness ratio HIV Benefit-cost ratio HCV Benefit-cost ratio HIV Cost-benefit ratio Total
Post SIF $2,182,800 11% 5 48 $45,475 $436,560 0.77 0.48 1.26
   (14%, 7%) (6, 3) (65, 31) (33,581, $70,413) ($363,800, $727,600) (1.1, 0.5) (0.58, 0.3) (1.63, 0.79)
Two SIF $2,182,800 8% 4 41 $53,239 $545,700 0.66 0.39 1.05
   (11%, 5%) (6, 3) (55, 26) ($39,687, $83,954) ($363,800, $727,600) (0.89, 0.42) (0.58, 0.3) (1.46, 0.71)
Three SIF $2,182,800 6% 2 24 $90,950 $1,091,400 0.39 0.19 0.58
   (9%, 4%) (3, 1) (28, 14) ($77,957, $155,914) ($727,600, $2,182,800) (0.45, 0.23) (0.29, 0.1) (0.74, 0.32)
Four SIF $2,182,800 5% 2 17 $128,400 $1,091,400 0.27 0.19 0.47
   (7%, 3%) (3, 1) (28, 13) ($77,957, $167,908) ($727,600, $2,182,800) (0.45, 0.21) (0.29, 0.1) (0.74, 0.31)
Five SIF $2,182,800 3% 2 21 $103,943 $1,091,400 0.34 0.19 0.53
   (5%, 2%) (3, 1) (28, 13) ($77,957, $167,908) ($727,600, $2,182,800) (0.45, 0.21) (0.29, 0.1) (0.74, 0.31)
Six SIF $2,182,800 2% 2 21 $103,943 $1,091,400 0.34 0.19 0.53
   (3%, 1%) (3, 1) (28, 13) ($77,957, $167,908) ($727,600, $2,182,800) (0.45, 0.21) (0.29, 0.1) (0.74, 0.31)
Seven SIF $2,182,800 1% 2 21 $103,943 $1,091,400 0.34 0.19 0.53
   (1%, 1%) (3, 1) (28, 13) ($77,957, $167,908) ($727,600, $2,182,800) (0.45, 0.21) (0.29, 0.1) (0.74, 0.31)
  1. Note: The numbers in parentheses represent the results of the sensitivity analysis: (30 per cent sharing rate, 10 percent sharing rate).